Analytic for Hemodynamic Instability (AHI) vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Analytic for Hemodynamic Instability (AHI)

by Fifth Eye

EchoNext

by Pathway Labs

AI Verdict

Fifth Eye's AHI System focuses on continuous, real-time monitoring of in-hospital patients to predict hemodynamic instability hours in advance using ECG lead II data. In contrast, Pathway Labs' EchoNext analyzes standard 12-lead ECGs to detect hidden structural heart diseases like heart failure, valve disease, and pulmonary hypertension, acting as an early diagnostic screening tool. While both utilize AI and ECG data in cardiology, their applications differ significantly in their timing and purpose within the patient care pathway.

Choose Analytic for Hemodynamic Instability (AHI) if…

Choose Analytic for Hemodynamic Instability (AHI) if you need continuous, real-time monitoring of adult in-hospital patients to predict hemodynamic instability hours before traditional vital signs. This tool is ideal for critical care settings, emergency departments, and telemetry units where early detection of patient deterioration can enable proactive intervention and improve outcomes.

View Analytic for Hemodynamic Instability (AHI) →

Choose EchoNext if…

Choose EchoNext if you are looking for an AI-powered solution to screen for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard 12-lead ECGs. This tool is best suited for broad access in various clinical settings, from major hospitals to community practices, to identify at-risk patients who may require further diagnostic testing like echocardiograms.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Analytic for Hemodynamic Instability (AHI)	EchoNext
Pricing	Contact vendor	Starts at $600/month
Deployment	Software as a Medical Device (SaMD) integrated into in-hospital monitoring platforms; accessible via any browser-enabled device.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Analytic for Hemodynamic Instability (AHI)

AHI System is designed for continuous, real-time monitoring and provides easy-to-interpret visual indicators (red, yellow, green), reducing nurse surveillance burden and streamlining workflow. It integrates with existing in-hospital monitoring platforms and is accessible via any browser-enabled device, simplifying deployment and use.

Clinical Value

Analytic for Hemodynamic Instability (AHI)

AHI System predicts hemodynamic instability hours ahead of traditional vital signs, with AHI-PI offering up to 26 hours lead time and identifying risk in 93% of Rapid Response Team events. This early warning allows for proactive patient care and intervention, potentially preventing serious outcomes.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, including details on implementation fees and annual discounts, which provides clarity for potential buyers. In contrast, AHI System's pricing is not specified, requiring direct vendor contact. While both offer clinical value, EchoNext's transparent pricing gives it an edge in this dimension.

Enterprise Readiness

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, indicating broad accessibility and integration capabilities for major hospitals to community practices. It also has explicit HIPAA compliance and a Business Associate Agreement (BAA) in place. AHI System is likely HIPAA compliant and offers BAA, but requires contacting the vendor for details.

Innovation

EchoNext

EchoNext represents a significant innovation by being the first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a capability previously not possible with ECGs alone. It has demonstrated higher accuracy than cardiologists in detecting these conditions. AHI System is also innovative in predicting hemodynamic instability earlier than vital signs, but EchoNext's ability to unlock new diagnostic potential from a routine test gives it a slight edge.

Support & Docs

Tie

Both tools are FDA-cleared, implying a level of regulatory documentation and validation. However, specific details regarding ongoing customer support, training programs, or publicly available documentation beyond their core functionalities are not extensively provided for either tool in the given information or search results.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Analytic for Hemodynamic Instability (AHI)	EchoNext
Tool Name	Analytic for Hemodynamic Instability (AHI)	EchoNext
Company	Fifth Eye	Pathway Labs
Description	FDA-cleared, AI-driven clinical decision support software that continuously monitors adult in-hospital patients for signs of hemodynamic instability, providing early warnings hours ahead of traditional vital signs.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Functionality	Predicts hemodynamic instability earlier than vital signs (up to 26 hours for AHI-PI) using continuous ECG lead II data.	Detects hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard 12-lead ECGs.

Videos

Demos, reviews, and walkthroughs featuring Analytic for Hemodynamic Instability (AHI) and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

AHI System integrates with in-hospital monitoring platforms like Sickbay and VitalConnect, embedding its capabilities directly to streamline workflow and reduce nurse surveillance burden. EchoNext is available through the OpenEvidence clinical decision support platform, aiming to integrate its screening output directly into tools physicians already use during patient visits, avoiding separate workflows.

What is the accuracy and sensitivity of each tool in detecting the conditions they target?

AHI System demonstrated 96% sensitivity and 85% specificity in detecting hemodynamic instability (hypotension plus tachycardia) in an FDA-reviewed study. AHI-PI, a component of the AHI System, predicted 93% of Rapid Response Team events with a median lead time of over 26 hours, significantly outperforming traditional vital signs. EchoNext correctly identified 77% of structural heart problems from ECGs alone, compared to cardiologists' 64% accuracy, and achieved an AUROC of 85% in internal tests and 78-80% in external validation.

What is the learning curve for physicians and clinical staff to effectively use these AI tools?

AHI System is designed with easy-to-interpret visual indicators (red, yellow, green) and provides real-time insights, which may contribute to a reduced learning curve for clinicians. EchoNext integrates with the OpenEvidence platform, which is already used by many clinicians, potentially easing adoption by embedding the AI's output into familiar interfaces.

What kind of customer support and training are available for these tools?

While specific details on support quality are not provided, both companies offer advanced AI-driven solutions, suggesting a need for robust customer support. Fifth Eye emphasizes that AHI System helps hospitals prevent adverse events and improve patient throughput, implying a commitment to successful implementation and use. Pathway Labs' partnership with OpenEvidence aims for broad access and integration, which would necessitate adequate support for widespread adoption.

What are the audit trail features for these tools to ensure accountability and review of AI-assisted decisions?

The provided information does not explicitly detail specific audit trail features for either Tool A (AHI System) or Tool B (EchoNext). However, as clinical decision support software, it is generally expected that such tools would incorporate mechanisms for tracking AI-generated insights and subsequent clinical actions for accountability and review. The FDA's guidance on AI in healthcare often emphasizes the importance of transparency and explainability, which would typically include audit capabilities.

How do these tools handle multi-site rollouts and ensure consistent performance across different clinical environments?

AHI System is integrated into existing in-hospital monitoring platforms and can be accessed via any browser-enabled device, suggesting flexibility for multi-site deployment. EchoNext has shown robust performance in studies representing over 20 hospitals and 500,000 patients across the United States and Canada, and its integration with OpenEvidence aims for availability in major hospitals to community practices, indicating consideration for diverse clinical environments.

In what clinical contexts would each tool be most beneficial, and are there specific patient populations where one might be preferred over the other?

AHI System is most beneficial for continuous monitoring of adult in-hospital patients at risk of hemodynamic instability, providing early warnings hours before traditional vital signs, particularly in critical care and emergency settings. EchoNext is designed for broad screening to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs, making it valuable for early detection in a wide range of patients from major hospitals to community practices.